274. Osteogenesis Imperfecta
78 clinical trials,   87 drugs   (DrugBank: 19 drugs),   14 drug target genes,   74 drug target pathways

Searched query = "Osteogenesis Imperfecta"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2004-001666-40-GB
(EUCTR)
14/06/200513/05/2005An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202EAn international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202E Osteogenesis ImperfectaProduct Name: zoledronic acid
Product Code: ZOL446
Novartis Pharma AGNULLNot RecruitingFemale: yes
Male: yes
130Hungary;United Kingdom
2EUCTR2004-001666-40-HU
(EUCTR)
01/02/200525/11/2004An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202EAn international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202E Osteogenesis ImperfectaProduct Name: zoledronic acid
Product Code: ZOL446
Novartis Pharma AGNULLNot RecruitingFemale: yes
Male: yes
130Hungary;United Kingdom
3EUCTR2004-001666-40-BE
(EUCTR)
05/09/2005An international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202EAn international, multicenter, randomized, open-label, safety andefficacy trial of intravenous zoledronic acid administered eitheronce or twice yearly in children with severe osteogenesisimperfecta, a 1-year extension to CZOL446H2202 - 2202E Osteogenesis ImperfectaProduct Name: zoledronic acid
Product Code: ZOL446
Novartis Pharma AGNULLNot RecruitingFemale: yes
Male: yes
130Phase 2Hungary;Belgium;United Kingdom